VanEck Associates
ELAT

VanEck Associates’s Elanco Animal Health Incorporated 5.00% Tangible Equity Units ELAT Stock Holding History

VanEck Associates’s Portfolio ELAT Stock Details ELAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-173,535
Closed -$3.39M – 1460
2022
Q4 		$3.39M Buy
173,535
+1,763
+1% +$35.4K 0.01% 558
2022
Q3 		$3.59M Buy
171,772
+25,021
+17% +$715K 0.01% 513
2022
Q2 		$4.7M Buy
146,751
+21,938
+18% +$827K 0.01% 476
2022
Q1 		$5.08M Sell
124,813
-6,997
-5% -$293K 0.01% 501
2021
Q4 		$5.89M Buy
131,810
+5,635
+4% +$271K 0.01% 472
2021
Q3 		$6.29M Buy
126,175
+14,951
+13% +$779K 0.02% 429
2021
Q2 		$5.97M Sell
111,224
-7,923
-7% -$398K 0.01% 433
2021
Q1 		$5.47M Buy
119,147
+10,802
+10% +$519K 0.01% 427
2020
Q4 		$5.29M Buy
108,345
+4,454
+4% +$213K 0.02% 372
2020
Q3 		$4.61M Sell
103,891
-2,218
-2% -$93.6K 0.01% 354
2020
Q2 		$4.08M Sell
106,109
-5,505
-5% -$222K 0.01% 363
2020
Q1 		$4.59M Buy
+111,614
New +$5.34M 0.02% 322

VanEck Associates's ELAT Position: Q1 2023 in Review

VanEck Associates sold out of Elanco Animal Health Incorporated 5.00% Tangible Equity Units (ELAT) in Q1 2023, closing a stake of 173,535 shares — an estimated $3.39M sold.

VanEck Associates first reported a position in ELAT in Q1 2020 and held it in 12 quarters. The position peaked at $6.29M in Q3 2021. 0 funds tracked by Wall St. Rank hold ELAT as of Q1 2023.

  • VanEck Associates reported no remaining Elanco Animal Health Incorporated 5.00% Tangible Equity Units position as of Q1 2023 after selling out during the quarter.
  • VanEck Associates sold 173,535 Elanco Animal Health Incorporated 5.00% Tangible Equity Units shares in Q1 2023, an estimated $3.39M.
  • VanEck Associates first reported a position in Elanco Animal Health Incorporated 5.00% Tangible Equity Units in Q1 2020 and held it in 12 quarters.
  • VanEck Associates's Elanco Animal Health Incorporated 5.00% Tangible Equity Units position peaked at $6.29M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Elanco Animal Health Incorporated 5.00% Tangible Equity Units as of Q1 2023.

Based on VanEck Associates's 13F filing for Q1 2023, filed 3 May 2023.